Cortometrajes de vídeo

Over the last decade we have seen emergence of increasing novel therapies like targeted therapy and immunotherapy & this has changed the natural history of disease for patients living with cancer including those with advanced disease.

Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.

In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.

Patients with Multiple Myeloma and plasma cell disorders are at high risk of infections because of compromised immune system. Associated co morbidities can also increase susceptibility to certain infections.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.